With submicromolar IC50 values against c-Met and VEGFR-2, the compound exhibited extraordinary dual inhibitory activity, demonstrating its capacity to concurrently disrupt two key signaling pathways associated with breast cancer angiogenesis, proliferation, and metastasis. Here, MET is linked to breast carcinoma.